Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

The General Dynamics announced a quarterly dividend

6/8/23 GD

PhosAgro will continue to pay dividends on a quarterly basis

6/7/23 PHOR

Univar Solutions shareholders agree to sell company

6/7/23 UNVR

The UnitedHealth Group announced a quarterly dividend

6/7/23 UNH

Board of Directors of Kamaz recommended that dividends be paid for 2022

6/7/23 KMAZ

Yandex launched an unmanned cab in Moscow

6/7/23 YNDX

Kazakhstan platform ITS will not work with Russian brokers and securities

6/7/23 SPBE

VTB will not disclose its new shareholders

6/7/23 VTBR

VTB reported for 4 months of 2023 by IFRS

6/7/23 VTBR

Board of Directors of Lenzoloto recommended that dividends be paid for 2022

6/7/23 LNZL